论文部分内容阅读
目的观察普萘洛尔在家族性肝癌肝动脉栓塞化疗(transcatheter arterial chemoembolization,TACE)围术期应用的安全性和近期疗效。方法 TACE术前3天开始口服普萘洛尔,自10mg/次起,逐日增加5mg至20mg/次,3次/天,术后继续口服普萘洛尔共4w。结果 9例患者共接受TACE治疗21次,平均2.3次(1～4次)。9名患者均可评价疗效,其中CR2例,PR4例,SD1,PD2例,RR67.7%(6/9)。6个月生存率88.9%(8/9),12个月生存率66.7(6/9),18个月生存率33.3%(3/9)。介入并发症主要有呕吐1例,腹痛6例,发热4例。毒副反应中性粒细胞Ⅲ抑制1例,无Ⅳ度抑制。结论普萘洛尔在家族性肝癌患者TACE围术期应用的近期有效率67.7%,未观察到严重和特别的并发症及毒副反应。
Objective To investigate the perioperative safety and short-term efficacy of propranolol in the treatment of familial hepatocellular carcinoma (HCC) with transcatheter arterial chemoembolization (TACE). Methods Propranolol was started orally 3 days prior to TACE. Propranolol was orally administered for 4 weeks after starting 10 mg / time, increasing 5 mg to 20 mg / time and 3 times daily. Results TACE was performed in 9 patients for 21 times, with an average of 2.3 times (1 ~ 4 times). Efficacy was evaluated in all 9 patients, including CR2, PR4, SD1, and PD2, and RR of 67.7% (6/9). The 6-month survival rate was 88.9% (8/9), the 12-month survival rate was 66.7 (6/9) and the 18-month survival rate was 33.3% (3/9). Interventional complications mainly vomiting in 1 case, abdominal pain in 6 cases, fever in 4 cases. Toxic side effects of neutrophil Ⅲ inhibition in 1 case, no degree of inhibition. Conclusion The recent effective rate of propranolol in the perioperative application of TACE in patients with familial liver cancer is 67.7%. No serious or special complications and adverse reactions have been observed.